Expanding the use of administrative claims databases in conducting clinical real-world evidence studies in multiple sclerosis

References

• Multiple Sclerosis International Federation. Atlas of MS database, 2013. Available at: http://www.atlasofms.org/index.aspx [Last accessed 23 April 2014]
   Google Scholar
• Compston A, Coles A. Multiple sclerosis. Lancet 2002;359:1221-31
   PubMed Web of Science ®Google Scholar
• Weinshenker BG, Bass B, Rice GP, et al. The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability. Brain 1989;112 (Pt 1):133-46
   PubMed Web of Science ®Google Scholar
• Derwenskus J. Current disease-modifying treatment of multiple sclerosis. Mt Sinai J Med 2011;78:161-75
   PubMed Web of Science ®Google Scholar
• Rojas JI, Romano M, Ciapponi A, et al. Interferon beta for primary progressive multiple sclerosis. Cochrane Database Syst Rev 2010 Jan 20;(1):CD006643. doi: 10.1002/14651858.CD006643.pub3
   Google Scholar
• Chastek BJ, Oleen-Burkey M, Lopez-Bresnahan MV. Medical chart validation of an algorithm for identifying multiple sclerosis relapse in healthcare claims. J Med Econ 2010;13:618-25
   PubMedGoogle Scholar
• Halpern R, Agarwal S, Borton L, et al. Adherence and persistence among multiple sclerosis patients after one immunomodulatory therapy failure: retrospective claims analysis. Adv Ther 2011;28:761-75
   PubMed Web of Science ®Google Scholar
• Kleinman NL, Beren IA, Rajagopalan K, Brook RA. Medication adherence with disease modifying treatments for multiple sclerosis among US employees. J Med Econ 2010;13:633-40
   PubMedGoogle Scholar
• Tan H, Cai Q, Agarwal S, et al. Impact of adherence to disease-modifying therapies on clinical and economic outcomes among patients with multiple sclerosis. Adv Ther 2011;28:51-61
   PubMed Web of Science ®Google Scholar
• Asche CV, Singer ME, Jhaveri M, et al. All-cause health care utilization and costs associated with newly diagnosed multiple sclerosis in the United States. J Manag Care Pharm 2010;16:703-12
   PubMed Web of Science ®Google Scholar
• Prescott JD, Factor S, Pill M, Levi GW. Descriptive analysis of the direct medical costs of multiple sclerosis in 2004 using administrative claims in a large nationwide database. J Manag Care Pharm 2007;13:44-52
   PubMed Web of Science ®Google Scholar
• Rajagopalan K, Brook RA, Beren IA, Kleinman NL. Comparing costs and absences for multiple sclerosis among US employees: pre- and post-treatment initiation. Curr Med Res Opin 2011;27:179-88
   PubMed Web of Science ®Google Scholar
• Reynolds MW, Stephen R, Seaman C, Rajagopalan K. Healthcare resource utilization following switch or discontinuation in multiple sclerosis patients on disease modifying drugs. J Med Econ 2010;13:90-8
   PubMedGoogle Scholar
• World Health Organization. International Classification of Diseases, Ninth Revision, Clinical Modification, 2010. Available at: http://www.cdc.gov/nchs/icd/icd9cm.htm [Last accessed 23 April 2014]
   Google Scholar
• Castelli-Haley J, Oleen-Burkey MA, Lage MJ, Johnson K. Glatiramer acetate and interferon beta-1a for intramuscular administration: a study of outcomes among multiple sclerosis intent-to-treat and persistent-use cohorts. J Med Econ 2010;13:464-71
   PubMedGoogle Scholar
• Ollendorf DA, Castelli-Haley J, Oleen-Burkey M. Impact of co-prescribed glatiramer acetate and antihistamine therapy on the likelihood of relapse among patients with multiple sclerosis. J Neurosci Nurs 2008;40:281-90
   PubMed Web of Science ®Google Scholar
• Dorrance KA, Ramchandani S, Neil N, Fisher H. Leveraging the military health system as a laboratory for health care reform. Mil Med 2013;178:142-5
   PubMed Web of Science ®Google Scholar
• Epstein M, International Society of P. Guidelines for good pharmacoepidemiology practices (GPP). Pharmacoepidemiol Drug Saf 2005;14:589-95
   PubMed Web of Science ®Google Scholar
• von Elm E, Altman DG, Egger M, et al. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. Prev Med 2007;45:247-51
   PubMed Web of Science ®Google Scholar
• Marrie RA, Yu N, Blanchard J, et al. The rising prevalence and changing age distribution of multiple sclerosis in Manitoba. Neurology 2010;74:465-71
   PubMed Web of Science ®Google Scholar
• Ingenix Normative Health Information Database. Available at: http://www.optum.com/life-sciences/develop-evidence/data-assets.html [Last accessed 30 April 2013]
   Google Scholar
• Margolis JM, Fowler R, Johnson BH, et al. Disease-modifying drug initiation patterns in commercially insured multiple sclerosis patients: a retrospective cohort study. BMC Neurol 2011;11:122
   PubMed Web of Science ®Google Scholar
• National Multiple Sclerosis Society. MS prevalence. Available at: http://www.nationalmssociety.org/about-the-society/ms-prevalence/index.aspx [Last accessed 22 June 2013]
   Google Scholar
• Capkun G, Lahoz R, Nordstrom B, et al. Exploring the identification of multiple sclerosis incident cohorts in claims databases: methodology and challenges. Value Health 2013;16:A582
   Google Scholar
• Polman CH, Reingold SC, Banwell B, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 2011;69:292-302
   PubMed Web of Science ®Google Scholar
• Capkun-Niggli G, Lahoz R, Verdun E, et al. Medical and pharmacy claims-based algorithms for identifying relapses in patients with multiple sclerosis. Value Health 2013;16:A582
   Google Scholar
• Bergvall N, Lahoz R, Reynolds T, Korn JR. Healthcare resource use and relapses with fingolimod versus natalizumab for treating multiple sclerosis: a retrospective US claims database analysis. Curr Med Res Opin 2014;30:1461-71
   PubMed Web of Science ®Google Scholar
• Bergvall N, Makin C, Lahoz R, et al. Comparative effectiveness of fingolimod versus interferons or glatiramer acetate for relapse rates in multiple sclerosis: a retrospective US claims database analysis. Curr Med Res Opin 2013;29:1647-56
   PubMed Web of Science ®Google Scholar
• Bergvall N, Makin C, Lahoz R, et al. Relapse rates in patients with multiple sclerosis switching from interferon to fingolimod or glatiramer acetate: a US claims database study. PLoS One 2014;9:e88472
   PubMed Web of Science ®Google Scholar
• Bergvall N, Petrilla A, Karkare SU, et al. Persistence with and adherence to fingolimod compared with other disease-modifying therapies for the treatment of multiple sclerosis: a retrospective US claims database analysis. J Med Econ 2014;17:696-707
   PubMedGoogle Scholar
• Novartis Pharma AG. Real-world Relapse and Hospitalization Rates in Multiple Sclerosis Literature Search. 2013
   Google Scholar
• Spelman T, Bergvall N, Tomic D, et al. Real-world comparative effectiveness of fingolimod and interferon/glatiramer therapies in a switch population using propensity-matched data from MSBase. Poster (P1096) presented at the 29th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), 2–5 October 2013, Copenhagen, Denmark
   Google Scholar
• Capkun G, Lahoz R, Chen W, et al. Comorbidities in patients with multiple sclerosis compared with a population without multiple sclerosis: an observational study using the US MarketScan Database. Mult Scler 2014;20(Suppl 1):147
   PubMedGoogle Scholar
• Capkun G, Nordstrom B, Lahoz R, et al. Mortality and morbidity in patients with multiple sclerosis compared with the general population: a retrospective analysis using the US Department of Defense Database. Mult Scler 2013;19(Suppl 1):349
   Google Scholar